MT1X: Detoxifying Xenobiotics (G4501)

Target Name: MT1X

NCBI ID: G4501

MT1X

MT1X: Detoxifying Xenobiotics

MT1X (Metallothionein-IX) is a protein that is expressed in many tissues throughout the body. It is a member of the thioredoxin gene family and is involved in the detoxification ofxenobiotics, such as arsenic and mercury, which are toxic to the body. MT1X is also involved in the regulation of inflammation and has been shown to have anti-inflammatory effects.

MT1X is a protein that is expressed in many tissues throughout the body, including the liver, spleen, and kidney. It is a member of the thioredoxin gene family and is encoded by the MTRX gene. This gene is located on chromosome 6p21 and has been shown to be involved in the detoxification of xenobiotics, such as arsenic and mercury, which are toxic to the body.

MT1X is a protein that is involved in the detoxification of xenobiotics, which are toxic to the body. It is a member of the thioredoxin gene family and is encoded by the MTRX gene. This gene is located on chromosome 6p21 and has been shown to be involved in

Protein Name: Metallothionein 1X

Functions: Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids. May be involved in FAM168A anti-apoptotic signaling (PubMed:23251525)

The "MT1X Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT1X comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets